BioWorld
@BioWorld

Biopharma’s trusted news source

 USA
bioworld.com/
Joined April 2009
478 Photos and videos
Jury awards $90M to Nektar in @EliLillyandCo dispute over rezpeg bioworld.com/articles/734368 #biopharma

Jury awards $90M to Nektar in Lilly dispute over rezpeg

A complaint filed in 2023 by Nektar Therapeutics Inc. against former partner Eli Lilly and Co. regarding development of Treg stimulator rezpegaldesleukin (rezpeg) ended this week with the jury...

bioworld.com
2
452
Blockbusters lift 2026 biopharma deal value to record $199B bioworld.com/articles/734305 #biopharma #deals @genentech @argenxglobal @ForteBio @KartosThera

Blockbusters lift 2026 biopharma deal value to record $199B

The value of biopharma deals has generally trended upward, despite year-over-year and month-to-month volatility. BioWorld’s records show the January-August total rose from $111.9 billion in 2019 to...

bioworld.com
393
China #biotechs engineer the next generation of #oncology therapies bioworld.com/articles/734304 #biopharma #ChinaBiotech #DrugDevelopment #ADC #TCellEngagers #dealmaking

China biotechs engineer the next generation of oncology therapies

New collaborations involving Henlius, Amberstone, Sanyou Bio and Novocodex highlight efforts to improve the safety, precision and efficacy of two fast-growing oncology modalities, T-cell engagers and...

bioworld.com
1
322
Nanexa’s $1.3B drug delivery #deal offers @novonordisk longer-acting #peptides bioworld.com/articles/734303 #biopharma

Nanexa’s $1.3B drug delivery deal offers Novo longer-acting peptides

In a continuous effort to improve its cardiometabolic franchise, Novo Nordisk A/S entered a deal worth up to €1.165 billion (US$1.325 billion) for a global exclusive license to Nanexa AB’s drug...

bioworld.com
2
2
510
.@AcadiaPharma mulls ADP phase III design as BMS Cobenfy data hover bioworld.com/articles/734301 #biopharma #Alzheimers #psychosis #5HT2A

Acadia push in ADP still alive after near miss in phase II

Acadia Pharmaceuticals Inc.’s near miss disclosed Sept. 24 in phase II with 5HT2A receptor inverse agonist remlifanserin in Alzheimer’s disease psychosis (ADP) was not altogether surprising, as...

bioworld.com
3
412
Another top #IPO: Adarx’s $446M to advance clinical #siRNA assets (free w/one-time registration) bioworld.com/articles/734300 #biopharma #financing

Another top IPO: Adarx’s $446M to advance clinical siRNA assets

At $446.3 million in gross proceeds, RNA-focused Adarx Pharmaceuticals Inc.’s IPO represents the fourth largest biopharma debut for 2026, a year that is proving to be the most prolific of any year...

bioworld.com
3
473
Remynd raises €3.5M to get novel Alzheimer’s program back on track bioworld.com/articles/734302 #biopharma #Alzheimers #financing

Remynd raises €3.5M to get novel Alzheimer’s program back on track

Remynd NV is back on track with its novel septin-targeting Alzheimer’s disease program after addressing liver toxicity problems and raising €3.5 million (US$4 million) from the Alzheimer’s Drug...

bioworld.com
2
415
Earendil’s #AI platform lands $1.5B Genentech collaboration bioworld.com/articles/734339… #biopharma #deal #oncology

Earendil’s AI platform lands $1.5B Genentech collaboration

In its second major collaboration announced this year, AI-focused Earendil Labs is pairing up with Roche Holding AG’s Genentech unit in a discovery deal aimed at developing bispecific antibody...

bioworld.com
813
Awiqli insulin, this time for @EliLillyandCo , with FDA-cleared #Onswik bioworld.com/articles/734337… #biopharma #FDAapproval #diabetes #insulin

Awiqli insulin, this time for Lilly, with FDA-cleared Onswik

Another long-acting insulin has cleared the U.S. FDA’s hurdle, with Eli Lilly and Co.’s Onswik (insulin efsitora alfa-gobe) winning approval for the type 2 diabetes community.

bioworld.com
603
An instinct about Atavistik? @Roche signs $1.9B-plus deal bioworld.com/articles/734338… #biopharma #deal #telangiectasia

An instinct about Atavistik? Roche signs $1.9B-plus deal

Privately held Atavistik Bio Inc. chalked a research collaboration with Roche AG to discover and develop small-molecule therapeutics against multiple targets for cardiovascular, renal and metabolic...

bioworld.com
2
1,088
Standing up to pressure key issue in Overton #confirmation hearing bioworld.com/articles/734336… #biopharma @HELPCmteDems @HELPGOP @US_FDA @WhiteHouse

Standing up to pressure key issue in Overton confirmation hearing

From the start, Heidi Overton’s confirmation hearing as U.S. FDA commissioner was shadowed by the broken promises Robert Kennedy made to the Senate Health, Education, Labor and Pensions Committee in...

bioworld.com
650
.@enveda raises a $311M series E for pipeline of plant-discovered molecules bioworld.com/articles/734335… #biopharma #financing

Enveda raises a $311M series E for pipeline of plant-discovered molecules

Enveda Therapeutics Inc. has doubled its valuation to approximately $2 billion in a $311 million series E financing, led by Catalio Capital Management, to support its pipeline of drugs to treat...

bioworld.com
626
FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer bioworld.com/articles/734293… #biopharma #cancer #cholangiocarcinoma #FDAapproval @ElevarTx

FGFR2 inhibitor Lyrfigtu wins FDA approval for bile duct cancer

Nearly two years after licensing Relay Therapeutics Inc.’s oral small-molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), lirafugratinib, Elevar Therapeutics Inc. won U.S. FDA approval...

bioworld.com
496
DME red flag in @Merck Brunello phase III? Surrozen finishes rich bioworld.com/articles/734292… #biopharma #DME #Wnt

DME red flag in Merck Brunello phase III? Surrozen finishes rich

Merck & Co. Inc.’s positive top-line data from the pivotal phase IIb/III Brunello trial with remigromig in adults with diabetic macular edema (DME) came with a possible safety downside, but backers...

bioworld.com
2
577
.@NIH grant process escaping @WhiteHouse threat? bioworld.com/articles/734340… #biopharma #medtech @AppropsDems @GOPHELP @SenateApprops @SenatorCollins @WHOMB

NIH grant process escaping White House threat?

In the face of immediate bipartisan backlash from key U.S. lawmakers and the research community, the Trump administration is reportedly backing away from a proposed executive order giving the White...

bioworld.com
481
.@GrailBio’s #Galleri test gets @US_FDA panel vote but concerns remain bioworld.com/articles/734295… #medtech #diagnostic #cancer

Grail’s Galleri test gets FDA panel vote but concerns remain

Even though the molecular and clinical genetics devices panel of the medical devices advisory committee for the U.S. FDA voted in favor of Grail Inc.’s Galleri multi-cancer early detection test, a...

bioworld.com
1
616
.@EliLillyandCo extends China innovation push in $3.35B Innocare deal (free w/one-time registration) bioworld.com/articles/734294… #biopharma #ChinaBiotech #drugdiscovery #licensing

Lilly extends China innovation push in $3.35B Innocare deal

Eli Lilly and Co. has struck another major China partnership, signing a discovery-stage collaboration with Beijing-based Innocare Pharma Ltd. worth up to $3.35 billion and reinforcing the U.S....

bioworld.com
1
606
N-of-1 therapies to address rare diseases with no commercial interest bioworld.com/articles/734297… #biopharma #science #research #raredisease

N-of-1 therapies to address rare diseases with no commercial interest

Despite considerable advances in diagnosis, new gene-modifying modalities and significant regulatory inducements, there remains a long tail of rare diseases that are below the threshold required for...

bioworld.com
1
2
553
Kasvu’s €30M series A to take novel #antidepressant into the clinic bioworld.com/articles/734296… #biopharma #financing

Kasvu’s €30M series A to take novel antidepressant into the clinic

Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small molecules that have the antidepressant benefits of psychedelic drugs, but...

bioworld.com
3
532
Med-tech #financings hit $14.6B as #IPO drought persists bioworld.com/articles/734214 #medtech @BridgetoLifeLTD @craif_jp @channel__med

Med-tech financings hit $14.6B as IPO drought persists

Med-tech financings totaled $14.58 billion through August 2026, down 23% from $19.01 billion in 2025 and the lowest eight-month total after 2023’s $11.73 billion. Volume dropped to 262 deals through...

bioworld.com
1
1
643
Load more